Myocardial remodeling in diabetic cardiomyopathy associated with cardiac mast cell activation

Area of Science:

• Cardiovascular Biology
• Endocrinology
• Pharmacology

Background:

• Diabetic cardiomyopathy is characterized by left ventricular remodeling and contractile dysfunction, distinct from other cardiac conditions.
• Hyperglycemia-induced metabolic byproducts can activate cardiac mast cells, contributing to myocardial remodeling via cytokine and enzyme release.
• Nedocromil, a mast cell stabilizer, has demonstrated potential in normalizing cytokine levels and mitigating cardiac remodeling.

Purpose of the Study:

• To investigate the role of cardiac mast cells in streptozotocin (STZ)-induced diabetic cardiomyopathy in mice.
• To evaluate the therapeutic efficacy of nedocromil in attenuating cardiac remodeling and contractile dysfunction in diabetic mice.

Main Methods:

• Diabetes was induced in normal mice using streptozotocin (STZ).
• Diabetic mice were treated with nedocromil for 12 weeks.
• Cardiac function, mast cell density, cytokine levels, and gene expression related to remodeling were assessed.

Main Results:

• Diabetic mice exhibited impaired cardiac function, increased cardiac mast cell density, and elevated mast cell secretions.
• Nedocromil treatment significantly improved cardiac function, reduced mast cell density, and normalized cytokine levels and extracellular matrix remodeling factors.
• Nedocromil treatment did not fully reverse all diabetic cardiomyopathy-associated changes, indicating other contributing pathways.

Conclusions:

• Cardiac mast cell activation plays a significant role in the pathogenesis of diabetic cardiomyopathy.
• Nedocromil effectively attenuates diabetic cardiomyopathy by targeting mast cell degranulation and associated inflammatory pathways.
• While nedocromil shows therapeutic promise, other cellular mechanisms also contribute to diabetic cardiomyopathy, suggesting combination therapies may be necessary.